Oncolytics gains as cancer treatment shows promise in mice

Oncolytics Biotech

20/09/2021 16:14

** U.S.-listed shares of the biotech company  ONCY.O  rise
5.7% to $2.12
    ** Says its experimental drug, pelareorep, combined with
radiotherapy led to statistically significant increase in
infiltrating anti-cancer T cells in mice with tumors (https://refini.tv/2ZfXM87)
    ** Says the combination led to a numerical increase in
survival
    ** Data presented at the International Conference on
Immunotherapy Radiotherapy Combinations
    ** Stock down ~11% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))